SAVI applicator removes obstacles associated with brachytherapy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 6
Volume 18
Issue 6

TORONTO-Studies out of the University of California, San Diego, have demonstrated that the SAVI radiation device offers coverage of the breast cancer tumor bed while sparing normal tissue from radiation.

TORONTO-Studies out of the University of California, San Diego, have demonstrated that the SAVI radiation device offers coverage of the breast cancer tumor bed while sparing normal tissue from radiation.

There were no infections, persistent seromas, or local recurrences of cancer among any of the patients in two separate investigations conducted by Daniel Scanderbeg, PhD, and Catheryn Yashar, MD, both from the university's Moores Cancer Center. They presented their findings at the 2009 American Brachytherapy Society meeting. Dr. Scanderbeg's group retrospectively evaluated 13 breast cancer patients with breast cancer tumor cavities less than 7 mm from the skin surface.

Dr. Yashar's team reviewed early clinical experiences with SAVI in 40 breast cancer patients, nearly half of whom were not candidates for balloon brachytherapy due to skin spacing or small tumor size. They concluded that the device allowed for planning flexibility, easier insertion, and minimal exposure.

Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content